| Mt Malcolm Mines NL (M2M) ORDINARY FULLY PAID |
Materials |
$5 |
Drilling to commence at Leonora on brownfields targets
|
8 May 2025 9:10AM |
$0.025 |
$0.009 |
fallen by
64%
|
|
M2M - Price-sensitive ASX Announcement
Full Release
Key Points
- Drilling to commence at Leonora brownfields targets.
- Focus is on the M2M prospect and surrounding high-priority sites.
- Targets selected based on historic data and recent exploration results.
- Program aims to test for extensions of known gold mineralization.
- Emphasis on near-term resource growth and value addition.
- Systematic exploration of established gold trends in the region.
- Drilling program set to start immediately.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sandfire Resources Limited (SFR) ORDINARY FULLY PAID |
Materials |
$7,801 |
Sale of Old Highway Gold Project
|
8 May 2025 9:09AM |
$10.350 |
$16.720 |
risen by
61.55%
|
|
SFR - Price-sensitive ASX Announcement
Full Release
Key Points
- Sandfire Resources entered an agreement to sell the Old Highway Gold Project to Auric Mining Limited.
- The sale consideration is up to A$1.5 million, including a cash component and milestone payments.
- An initial payment of A$300,000 is payable in cash upon completion.
- Additional payments are contingent on resource milestones and production royalties.
- The Old Highway Gold Project is located in Western Australia and is non-core to Sandfire’s current strategy.
- Sandfire retains certain royalty interests in the project.
- The divestment is part of Sandfire’s strategy to focus on copper assets and optimize its portfolio.
- The sale agreement includes customary warranties, conditions, and completion timing provisions.
- This transaction will strengthen Sandfire's balance sheet and aligns with its broader corporate strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Novatti Group Limited (NOV) ORDINARY FULLY PAID |
Information Technology |
$15 |
Resignation of Joint Company Secretary
|
8 May 2025 9:09AM |
$0.025 |
$0.025 |
fallen by
0%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,509 |
Update - Notification of buy-back - NEU
|
8 May 2025 9:08AM |
$12.620 |
$11.930 |
fallen by
5.47%
|
|
| Cygnus Metals Limited (CY5) ORDINARY FULLY PAID |
Materials |
$140 |
More High Grade Assays from Golden Eye
|
8 May 2025 9:08AM |
$0.081 |
$0.115 |
risen by
41.98%
|
|
CY5 - Price-sensitive ASX Announcement
Full Release
Key Points
- Further high-grade lithium assays reported from Golden Eye prospect at Pontax Lithium Project.
- Drill holes intersected wide and high-grade spodumene-bearing pegmatites.
- Notable lithium oxide grades, including several intersections over 1% Li2O.
- Results confirm potential for significant resource growth at Golden Eye.
- Golden Eye remains open along strike and at depth, with step-out drilling planned.
- Assay results enhance the strategic importance of Pontax within the James Bay lithium district.
- The company is advancing its exploration program with plans for additional drilling in 2024.
- Cygnus Metals continues to report consistent and encouraging lithium mineralization across multiple targets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Riversgold Limited (RGL) ORDINARY FULLY PAID |
Materials |
$37 |
Wodgina East Site Trip Completed
|
8 May 2025 9:08AM |
$0.004 |
$0.016 |
risen by
300%
|
|
| Centaurus Metals Limited (CTM) ORDINARY FULLY PAID |
Materials |
$354 |
Jaguar Value Engineering Enhances Project Economics
|
8 May 2025 9:07AM |
$0.380 |
$0.625 |
risen by
64.47%
|
|
CTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Centaurus Metals completed a value engineering review for the Jaguar Nickel Sulphide Project.
- Process plant flow sheet was optimized to simplify operations and enhance recoveries.
- Nickel recovery rates increased as a result of process improvements.
- Operating and capital costs for the project have been reduced.
- Mineral resource estimate was upgraded, strengthening the project's foundation.
- A more efficient nickel concentrate leaching process was adopted.
- Project economics have improved with higher projected nickel production and lower unit costs.
- The revised project enhances Centaurus Metals' position in the global nickel market.
- Environmental, Social, and Governance (ESG) considerations were integrated during the optimization process.
- The enhancements support a robust financial outlook and provide a pathway to project development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Minerals 260 Limited (MI6) ORDINARY FULLY PAID |
Materials |
$1,652 |
Proposed issue of securities - MI6
|
8 May 2025 9:07AM |
$0.130 |
$0.730 |
risen by
461.54%
|
|
| Centaurus Metals Limited (CTM) ORDINARY FULLY PAID |
Materials |
$354 |
Jaguar's Class-Leading Carbon Footprint Credentials Enhanced
|
8 May 2025 9:06AM |
$0.380 |
$0.625 |
risen by
64.47%
|
|
CTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Centaurus Metals Limited reaffirms Jaguar Nickel Project's low carbon footprint.
- Updated Life Cycle Assessment (LCA) shows globally leading low carbon intensity for nickel sulphate production.
- Jaguar's carbon intensity is significantly lower than conventional nickel producers.
- Key contributors: high-grade ore, hydropower, efficient processing, emission minimization.
- Results support demand for low-emission nickel in battery and EV supply chains.
- Centaurus emphasizes ongoing sustainability and environmental improvement at Jaguar.
- Project well-positioned to meet responsible sourcing requirements in global markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vertex Minerals Limited (VTX) ORDINARY FULLY PAID |
Materials |
$49 |
Trading Halt
|
8 May 2025 9:06AM |
$0.240 |
$0.170 |
fallen by
29.17%
|
|
VTX - Price-sensitive ASX Announcement
Full Release
Key Points
- Vertex Minerals Limited (ASX: VTX) requested a trading halt on 7 June 2023.
- The trading halt is due to a pending announcement concerning a capital raising.
- Trading in VTX securities will be halted until the capital raising announcement is made or until trading resumes on 9 June 2023.
- The request is made to ensure an orderly market while the company prepares its announcement.
- No further information is provided about the specifics of the capital raising within the trading halt request.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Belararox Limited (BRX) ORDINARY FULLY PAID |
Materials |
$17 |
MI6: Additional Tenements Contiguous to Bullabulling Secured
|
8 May 2025 9:04AM |
$0.076 |
$0.064 |
fallen by
15.79%
|
|
BRX - Price-sensitive ASX Announcement
Full Release
Key Points
- BRX, through its subsidiary, has secured new tenement applications adjacent to the Bullabulling Project in Western Australia.
- The additional tenements significantly increase the project’s exploration footprint.
- Exploration focus includes lithium, caesium, tantalum, rare earth elements, and gold.
- Recent regional discoveries and geological context suggest the new areas have high mineral potential.
- The acquired land is contiguous to BRX’s existing holdings, enhancing project scale and synergy.
- Proximity to infrastructure such as roads and rail supports future development potential.
- The company’s immediate plans include target generation and prioritisation for exploration activities.
- BRX aims to position itself as a leading explorer of critical minerals in Western Australia.
- The announcement outlines the geological setting, strategic rationale, and next steps for the expanded Bullabulling Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Minerals 260 Limited (MI6) ORDINARY FULLY PAID |
Materials |
$1,652 |
Additional Tenements Contiguous to Bullabulling Secured
|
8 May 2025 9:04AM |
$0.130 |
$0.730 |
risen by
461.54%
|
|
MI6 - Price-sensitive ASX Announcement
Full Release
Key Points
- Minerals 260 Limited announced acquisition of three additional tenements contiguous to Bullabulling.
- Tenements acquired are E15/2016, E15/2017, and E15/2018.
- Located within the Eastern Goldfields of Western Australia.
- Tenements are prospective for lithium, REE, gold, and base metals.
- Acquisition supports MI6’s growth and exploration strategy.
- MI6 will hold 100% ownership of the tenements upon completion.
- Exploration plans include mapping, sampling, and geophysical surveys.
- Acquisition completion is subject to Ministerial consent for transfer.
- Expansion enhances MI6’s project pipeline and regional presence.
- The Bullabulling area is known for significant mineral endowment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Waratah Minerals Limited (WTM) ORDINARY FULLY PAID |
Materials |
$220 |
Trading Halt
|
8 May 2025 9:04AM |
$0.305 |
$0.710 |
risen by
132.79%
|
|
WTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Waratah Minerals Limited (ASX: WTM) has requested a trading halt effective 12 June 2024.
- The trading halt is pending an announcement regarding a capital raising.
- The halt is expected to last until the earlier of the announcement release or the commencement of trading on 14 June 2024.
- The company is not aware of any reason the trading halt should not be granted.
- The request for the halt was lodged by company secretary Edwin Gien in accordance with ASX Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hutchison Telecommunications (Australia) Limited (HTA) ORDINARY FULLY PAID |
Communication Services |
- |
Chairman's Address to Shareholders
|
8 May 2025 9:04AM |
$0.026 |
$0.031 |
risen by
19.23%
|
|
| Latrobe Magnesium Limited (LMG) ORDINARY FULLY PAID |
Materials |
$56 |
Application for quotation of securities - LMG
|
8 May 2025 9:03AM |
$0.012 |
$0.018 |
risen by
50%
|
|
| Helloworld Travel Limited (HLO) ORDINARY FULLY PAID |
Consumer Discretionary |
$237 |
HLO trading trends
|
8 May 2025 9:03AM |
$1.425 |
$1.445 |
risen by
1.40%
|
|
HLO - Price-sensitive ASX Announcement
Full Release
Key Points
- HLO reported TTV of $1.94 billion, up 30.1% on the previous corresponding period.
- Revenue increased to $116.3 million, up 33.5% from the prior period.
- Underlying EBITDA was $45.1 million, up 42.1% year-on-year.
- Net profit after tax (NPAT) was $24.8 million, a 36.9% increase.
- Strong demand observed in both leisure and corporate travel markets.
- International business contributed significantly to growth, especially in New Zealand and Fiji.
- HLO’s corporate division experienced 23.7% TTV growth.
- The company declared a fully franked interim dividend of 10.0 cents per share.
- HLO’s balance sheet remains robust, with $146.1 million in cash and minimal debt.
- Positive trading trends have continued into the second half of FY24.
- HLO continues to invest in technology, people, and marketing to drive growth.
- The company remains focused on shareholder returns and strategic opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,509 |
DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
|
8 May 2025 9:02AM |
$12.620 |
$11.930 |
fallen by
5.47%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- DAYBUE net sales in the US for Q1 2025 were US$84.6 million, up 11% versus Q1 2024.
- Neuren received A$13.7 million in quarterly revenue from DAYBUE royalties and commercial milestones.
- DAYBUE is indicated for the treatment of Rett syndrome.
- DAYBUE demand in the US remains robust with positive patient and caregiver feedback.
- Preparations for the European launch of DAYBUE are underway with an expected launch in H2 2024.
- Clinical advancement for additional indications including Fragile X syndrome and Phelan-McDermid syndrome is ongoing.
- Neuren retains a strong balance sheet facilitating continued investment in R&D and pipeline growth.
- The company is focused on expanding the commercial and clinical potential of DAYBUE and related drug candidates.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| KKR Credit Income Fund (KKC) ORDINARY UNITS FULLY PAID |
Financials |
$674 |
Net Tangible Asset Backing
|
8 May 2025 9:02AM |
$2.210 |
$2.090 |
fallen by
5.43%
|
|
| Forrestania Resources Limited (FRS) ORDINARY FULLY PAID |
Materials |
$570 |
Top 20 securityholders
|
8 May 2025 9:01AM |
$0.039 |
$0.505 |
risen by
1,194.87%
|
|
| Coast Entertainment Holdings Limited (CEH) ORDINARY FULLY PAID |
Consumer Discretionary |
$177 |
Update - Notification of buy-back - CEH
|
8 May 2025 9:01AM |
$0.410 |
$0.455 |
risen by
10.98%
|
|
| Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$28 |
Peter Mac Partners with Algorae on AI Drug Targets
|
8 May 2025 9:01AM |
$0.007 |
$0.014 |
risen by
100%
|
|
1AI - Price-sensitive ASX Announcement
Full Release
Key Points
- Algorae Pharmaceuticals partners with Peter MacCallum Cancer Centre for AI-driven drug target discovery.
- Algorae’s proprietary 1AI platform will be used to identify and validate novel cancer drug targets.
- Peter Mac provides oncology expertise and biological data to support and validate 1AI findings.
- The collaboration aims to accelerate drug discovery and expand Algorae's IP portfolio.
- Potential to commercialize new therapeutics derived from AI-identified drug targets.
- The partnership exemplifies the transformative role of artificial intelligence in cancer research and drug development.
- Algorae’s strategy includes leveraging 1AI to improve efficiency and reduce risks in identifying promising drug targets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cadence Capital Limited (CDM) ORDINARY FULLY PAID |
Financials |
$219 |
Investment Update and NTA April 2025
|
8 May 2025 9:01AM |
$0.600 |
$0.735 |
risen by
22.50%
|
|
| Forrestania Resources Limited (FRS) ORDINARY FULLY PAID |
Materials |
$570 |
Appendix 3Y - Hannaford-Higgins-Raihani
|
8 May 2025 9:00AM |
$0.039 |
$0.505 |
risen by
1,194.87%
|
|
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$353 |
Change of Director's Interest Notice - Hehir
|
8 May 2025 9:00AM |
$0.225 |
$0.155 |
fallen by
31.11%
|
|
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$406 |
Update - Notification of buy-back - RG8
|
8 May 2025 8:59AM |
$1.660 |
$2.820 |
risen by
69.88%
|
|
Call 1300 880 160
Start a chat
Schedule a call
